Preventing and Treating Chagas Disease

SLU ID 15-008 | Trypanosoma cruzi vaccine targets

Intellectual Property Status

Seeking

  • Patented

  • Know-how based

  • Licensee

  • Development partner

  • Commercial partner

  • Investment

  • University spin out

Background

There are no available human vaccines for preventing or treating Trypanosoma cruzi infections, which cause Chagas disease.

Overview

Researchers at Saint Louis University have identified T-cell targets relevant to human Trypanosoma cruzi infections. They identified 30 new immunogenic HLA-A2-restricted CD8+ T-cell epitopes.

Benefits

The potential benefits of this technology include:

  • Increasing the number of treatments for Chagas disease

  • Minimizing the number of Trypanosoma cruzi infections

Applications

The potential applications of this technology include:

  • Preventing and treating Chagas disease

Opportunity

Saint Louis University is seeking a partner to further develop and commercialize this technology.